Re: Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019
in response toby
The choice of the word « improves » in the title is interesting. Does it mean cognitive function was better at the end of the trial than at the start, or only that the rate of decline was reduced (so that at the end of the trial CF was better in the ABL group than in the placebo group, but still lower than at baseline).
Either result would be very good, of course, but the former would be a dream. Here’s hoping!